Meltzer H Y, Fang V S
Arch Gen Psychiatry. 1983 May;40(5):501-5. doi: 10.1001/archpsyc.1983.01790050027003.
The possibility that unreliability of plasma cortisol level determinations might interfere with the use of the dexamethasone suppression test (DST) in clinical practice was evaluated by examining published data on the reliability of plasma cortisol determinations as well as a comparison of two radioimmunoassay (RIA) methods with a competitive protein binding assay (CPBA). Significant discrepancies between various methods of plasma cortisol level determinations have been reported in most, but not all, studies. The most widely used method, RIA kits, may not produce levels comparable with those produced by the CPBA, used in a recent effort to standardize the DST for use in psychiatry. The use of the DST by physicians should be preceded by an assessment of the validity of the cortisol level determinations in the critical range for the DST by the laboratory they use.
通过审查已发表的关于血浆皮质醇测定可靠性的数据，以及比较两种放射免疫测定（RIA）方法与竞争性蛋白结合测定（CPBA），评估了血浆皮质醇水平测定的不可靠性可能会干扰地塞米松抑制试验（DST）在临床实践中应用的可能性。在大多数（但不是所有）研究中，都报告了各种血浆皮质醇水平测定方法之间存在显著差异。最广泛使用的方法，即RIA试剂盒，可能无法产生与CPBA所产生的水平相当的结果，而CPBA是最近为使DST标准化以便用于精神病学所采用的方法。医生在使用DST之前，应由他们所使用的实验室评估皮质醇水平测定在DST关键范围内的有效性。
